Entity
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0

infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0

infinite
0
--
LPS:CD14
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0

infinite
0
--
csml-variable:Double
m12
0

infinite
0
--
csml-variable:Double
m13
0

infinite
0
--
P2X7
--
e14
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m14
0

infinite
0
--
LPS:P2X7
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m15
0

infinite
0
--
LPS: HSP70/HSP90/CXCR4/GDF
--
e16
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m16
0

infinite
0
--
LPS: CD55
--
e17
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m17
0

infinite
0
--
CR3
--
e18
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m18
0

infinite
0
--
LPS: CR3
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m19
0

infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0

infinite
0
--
TLR2
--
e20
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m20
0

infinite
0
--
LPS: TLR2
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m21
0

infinite
0
--
TLR4
--
e22
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m22
0

infinite
0
--
LPS: TLR4
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m23
0

infinite
0
--
csml-variable:Double
m24
0

infinite
0
--
LPS: TLR4: MyD88
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0

infinite
0
--
csml-variable:Double
m26
0

infinite
0
--
csml-variable:Double
m27
0

infinite
0
--
csml-variable:Double
m28
0

infinite
0
--
csml-variable:Double
m29
0

infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0

infinite
0
--
csml-variable:Double
m30
0

infinite
0
--
IKK-alpha/beta{activated}
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m31
0

infinite
0
--
csml-variable:Double
m32
0

infinite
0
--
p65/p50{activated}
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m33
0

infinite
0
--
TIRAP
--
e34
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m34
0

infinite
0
--
LPS: TLR4: TIRAP
--
e35
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0

infinite
0
--
csml-variable:Double
m36
0

infinite
0
--
csml-variable:Double
m37
0

infinite
0
--
csml-variable:Double
m38
0

infinite
0
--
csml-variable:Double
m39
0

infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0

infinite
0
--
csml-variable:Double
m40
0

infinite
0
--
p38MAPK{activated}
--
e41
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m41
0

infinite
0
--
csml-variable:Double
m42
0

infinite
0
--
csml-variable:Double
m43
0

infinite
0
--
csml-variable:Double
m44
0

infinite
0
--
csml-variable:Double
m45
0

infinite
0
--
csml-variable:Double
m46
0

infinite
0
--
csml-variable:Double
m47
0

infinite
0
--
csml-variable:Double
m48
0

infinite
0
--
csml-variable:Double
m49
0

infinite
0
--
LPS
--
e5
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m5
0

infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0

infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0

infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0

infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0

infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0

infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0

infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0

infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0

infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0

infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0

infinite
0
--
CD14
--
e6
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m6
0

infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0

infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0

infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0

infinite
0
--
csml-variable:Double
m63
0

infinite
0
--
csml-variable:Double
m64
0

infinite
0
--
p65/p50_nucleus
--
e65
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m65
0

infinite
0
--
csml-variable:Double
m66
0

infinite
0
--
pI-3 kinase{activated}
--
e67
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m67
0

infinite
0
--
csml-variable:Double
m68
0

infinite
0
--
csml-variable:Double
m69
0

infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0

infinite
0
--
csml-variable:Double
m70
0

infinite
0
--
IL-1ra
--
e71
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m71
0

infinite
0
--
csml-variable:Double
m72
0

infinite
0
--
csml-variable:Double
m73
0

infinite
0
--
csml-variable:Double
m74
0

infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0

infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0

infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m6*m5*0.1
nodelay
--

0

PMID: 12106784, 10706718 Epitope-mapping studies revealed that CD14 selectively recognizes E. coli, P. gingivalis and H. pylori LPSs and that hydrophilic domains of the amino-terminal region of CD14 are involved in LPS binding.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c30 : 1
stoichiometry:c29 : 1
m28*m27*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c33 : 1
stoichiometry:c32 : 1
m30*m29*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c36 : 1
stoichiometry:c35 : 1
m32*m31*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m34*m23*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c46 : 1
stoichiometry:c41 : 1
m36*m35*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c42 : 1
stoichiometry:c47 : 1
stoichiometry:c43 : 1
m38*m37*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c48 : 1
stoichiometry:c45 : 1
m40*m39*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c52 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c55 : 1
stoichiometry:c50 : 1
m44*m41*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c51 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m14*m5*0.1
nodelay
--

0

PMID: 12106784, 11489964 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55 , HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c61 : 1
stoichiometry:c60 : 1
m48*m37*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c64 : 1
stoichiometry:c63 : 1
m40*m49*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c67 : 1
stoichiometry:c66 : 1
m63*m41*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
m33*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c72 : 1
stoichiometry:c71 : 1
m66*m23*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m67*m32*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
m65*0.1
nodelay
--

0

PMID: 12106784 Fig.4
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c53 : 1
m65*0.1
nodelay
--

0

PMID: 12106784 Fig.4
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c78 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c88 : 1
stoichiometry:c84 : 1
m41*0.1
nodelay
--

0

PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m12*m5*0.1
nodelay
--

0

PMID: 12106784, 10219599 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55, HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c80 : 1
m11*0.1
nodelay
--

0

PMID: 12106784, 9767415 LPS-induced IL-1 production is mediated by CD14-dependent mechanisms in the presence of plasma, whereas in its absence, both CD14-dependent and CD14-independent pathways are involved.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c81 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 9767415 LPS-induced IL-1 production is mediated by CD14-dependent mechanisms in the presence of plasma, whereas in its absence, both CD14-dependent and CD14-independent pathways are involved.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c85 : 1
m41*0.1
nodelay
--

0

PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c86 : 1
m41*0.1
nodelay
--

0

PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c92 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c91 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c90 : 1
m23*0.1
nodelay
--

0

PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m13*m5*0.1
nodelay
--

0

PMID: 12106784, 11276205 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55 , HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m18*m5*0.1
nodelay
--

0

PMID: 12106784 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55, HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m11*m20*0.1
nodelay
--

0

PMID: 12106784 Genetic approaches have involved TLR2 and TLR4 in LPS recognition.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c58 : 1
m11*m22*0.1
nodelay
--

0

PMID: 12106784 Genetic approaches have involved TLR2 and TLR4 in LPS recognition.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m23*m24*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m25*m26*0.1
nodelay
--

0

PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--